07:46 AM EST, 11/15/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency's has recommended the approval of repotrectinib to treat certain patients with advanced non-small cell lung cancer and advanced solid tumors.

The recommendation was based on two trials, in which repotrectinib demonstrated "clinically meaningful" response rates and a "well characterized" safety profile, Bristol-Myers said.

The European Commission will review the committee's recommendation, with a final approval decision expected in January 2025.

Price: 54.52, Change: +0.20, Percent Change: +0.37